Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.10 per share a year ago.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
1 No-Brainer Stock to Buy With $40
The midcap biotech just became an even better buy.
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Attractive Biotechs With Recent Positives
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against many names in this area, a covered call strategy has worked quite successfully for my portfolio on a consistent basis.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY). But which of these two companies is the best option for those looking for undervalued stocks?
Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials
Exelixis' stock has surged 51% since July 2023, significantly outperforming broader markets and breaking out of a five-year stagnation. Cabometyx, EXEL's primary revenue driver, continues to excel in renal cell carcinoma, generating strong sales and bolstering financial stability. The company settled patent disputes, delaying generic entry for Cabometyx until 2031, providing a critical extension of its revenue stream.
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Exelixis Gets Favorable Ruling in Patent Litigation With MSN
The Delaware District Court ruled in EXEL's favor, rejecting MSN's challenge to three patents related to cabozantinib.
